Updates
Developments
A running, dated record of what is actually moving in the FDA’s review of these peptides — each entry tied to primary filings and major reporting, with a plain-English read on what it changes. Newest first.
July 1, 2026
FDA review staff recommend against all seven peptides
Ahead of the July 23–24 meeting, the FDA released its briefing materials, and the agency’s own review staff concluded that the available evidence does not support adding the seven peptides to the 503A bulks list — pointing to limited human data and unresolved safety questions for several of the substances. The assessment is notable because it runs against the publicly stated position of HHS Secretary Robert F. Kennedy Jr., who has favored broader peptide access.
What it means: PCAC is advisory. The committee weighs this staff review alongside the nominators’ presentations and public comment, then votes on non-binding recommendations; the FDA decides afterward whether to begin rulemaking. A staff “no” does not settle the outcome, but it raises the bar and sets up a visible split between FDA scientists and department leadership.
June 29, 2026
Advisory committee seated — and its membership draws scrutiny
The FDA named the members who will sit for the July meeting, bringing the panel to 14. Reporting noted that roughly half of the seated members have professional ties to businesses or clinics involved in peptide therapies, prompting conflict-of-interest questions; HHS said every member completed the same ethics review required of all advisory-committee members.
What it means: This resolves the earlier open question of whether the committee would be large enough to vote. It also makes the panel’s composition — and how it weighs the FDA staff review against nominator data — a storyline in its own right heading into the vote.
April 16, 2026
The meeting is formally noticed
The FDA published a Federal Register notice scheduling the PCAC meeting for July 23–24, 2026 and opening a public docket (FDA-2025-N-6895). Day 1 covers BPC-157, KPV, TB-500 and MOTS-c; Day 2 covers Emideltide (DSIP), Semax and Epitalon. A separate meeting before the end of February 2027 is slated to review five more substances, including GHK-Cu and Melanotan II.
What it means: This set the agenda and the public-comment timeline running up to the vote — and confirmed that GHK-Cu and Melanotan II are in the later batch, so their status does not change on July 23–24.
April 15, 2026
The peptides leave Category 2 — but not because they were cleared
The FDA noticed the removal of the same seven peptides from 503A Category 2, effective after seven days. The removal followed the withdrawal of the underlying nominations — by LDT Health Solutions (a consulting firm representing the International Peptide Society) and the Wells Pharmacy Network — not any safety finding. The FDA said it would review the substances at PCAC regardless.
What it means: Leaving Category 2 is not the same as moving to Category 1. It does not authorize compounding and does not grant enforcement discretion; the substances sit in a regulatory gap pending the July review. This is the single most-misreported point in the whole story — “off Category 2” has been widely miswritten as “legal again.”
The Compounding Brief
Get the next update by email
We email when a peptide’s status actually moves — committee votes, briefing documents, final rules — plus the occasional licensed-access update. No hype, no filler.
Free. Unsubscribe anytime. We never share your email. Not medical advice.